| Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. HL Weiner, A Friedman, A Miller, SJ Khoury, A Al-Sabbagh, L Santos, ... Annual review of immunology 12, 809-837, 1994 | 1160 | 1994 |
| Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta … A Miller, O Lider, AB Roberts, MB Sporn, HL Weiner Proceedings of the National Academy of Sciences 89 (1), 421-425, 1992 | 954 | 1992 |
| Antigen-driven bystander suppression after oral administration of antigens. A Miller, O Lider, HL Weiner The Journal of experimental medicine 174 (4), 791-798, 1991 | 559 | 1991 |
| Revised diagnostic criteria of multiple sclerosis R Milo, A Miller Autoimmunity reviews 13 (4-5), 518-524, 2014 | 532 | 2014 |
| Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules MK Nakhleh, H Amal, R Jeries, YY Broza, M Aboud, A Gharra, H Ivgi, ... ACS nano 11 (1), 112-125, 2017 | 528 | 2017 |
| Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status A Miller, S Dishon Quality of life research 15, 259-271, 2006 | 457 | 2006 |
| Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring L Kappos, D Bates, G Edan, M Eraksoy, A Garcia-Merino, N Grigoriadis, ... The Lancet Neurology 10 (8), 745-758, 2011 | 387 | 2011 |
| Treatment of multiple sclerosis with copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation A Miller, S Shapiro, R Gershtein, A Kinarty, H Rawashdeh, S Honigman, ... Journal of neuroimmunology 92 (1-2), 113-121, 1998 | 304 | 1998 |
| Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells H Ochi, M Abraham, H Ishikawa, D Frenkel, K Yang, AS Basso, H Wu, ... Nature medicine 12 (6), 627-635, 2006 | 286 | 2006 |
| Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation Y Ben-Yosef, N Lahat, S Shapiro, H Bitterman, A Miller Circulation research 90 (7), 784-791, 2002 | 268 | 2002 |
| Vitamin B12, demyelination, remyelination and repair in multiple sclerosis A Miller, M Korem, R Almog, Y Galboiz Journal of the neurological sciences 233 (1-2), 93-97, 2005 | 266 | 2005 |
| A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis MB Bornstein, A Miller, S Slagle, M Weitzman, E Drexler, M Keilson, ... Neurology 41 (4), 533-533, 1991 | 257 | 1991 |
| Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases E Ben-Ami, S Berrih-Aknin, A Miller Autoimmunity reviews 10 (7), 410-415, 2011 | 237 | 2011 |
| Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis HS Panitch, RA Thisted, RA Smith, DR Wynn, JP Wymer, A Achiron, ... Annals of Neurology: Official Journal of the American Neurological …, 2006 | 205 | 2006 |
| Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. A Miller, A Al-Sabbagh, LM Santos, MP Das, HL Weiner Journal of immunology (Baltimore, Md.: 1950) 151 (12), 7307-7315, 1993 | 202 | 1993 |
| Auditory feedback control for improvement of gait in patients with Multiple Sclerosis Y Baram, A Miller Journal of the neurological sciences 254 (1-2), 90-94, 2007 | 186 | 2007 |
| Virtual reality cues for improvement of gait in patients with multiple sclerosis Y Baram, A Miller Neurology 66 (2), 178-181, 2006 | 183 | 2006 |
| Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments A Miller, H Pratt, RB Schiffer Expert Review of Neurotherapeutics 11 (7), 1077-1088, 2011 | 162 | 2011 |
| Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon‐β therapy in relapsing and secondary‐progressive multiple … Y Galboiz, S Shapiro, N Lahat, H Rawashdeh, A Miller Annals of Neurology: Official Journal of the American Neurological …, 2001 | 159 | 2001 |
| Antigen‐driven tissue‐specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein‐induced experimental autoimmune … A Al‐Sabbagh, A Miller, LMB Santos, HL Weiner European journal of immunology 24 (9), 2104-2109, 1994 | 158 | 1994 |
